← Back to headlines
Novo Nordisk Shares Plunge After Obesity Drug Fails to Outperform Zepbound
Novo Nordisk's shares dropped significantly after its new obesity drug did not demonstrate superior efficacy compared to Zepbound.
23 Feb, 16:44 — 23 Feb, 16:44
Sources
Showing 1 of 1 sources
Related Stories
Homeland Security Secretary’s Plane Makes Emergency Landing After Engine Failure
31m ago
Berkshire Hathaway Signals Long-Term Commitment to Japanese Trading Houses
41m ago
South Korean Utility Proposes $15 Billion Upfront Power Payment From Samsung
1h ago
Chevron Confirms Expansion of Oil Operations in Venezuela
1h ago